[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100091376":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":7,"locations":7,"responsibleParty":17,"collaborators":7,"id":19,"slug":20,"hasResults":21,"nctId":22,"briefTitle":23,"officialTitle":24,"acronym":7,"eligibilityCriteria":25,"healthyVolunteers":21,"sex":26,"minAge":27,"maxAge":7,"enrollmentInfo":28,"targetDuration":7,"studyType":31,"phases":32,"briefSummary":34,"conditions":35,"keywords":7,"overallStatus":37,"whyStopped":7,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":7},{"fullName":5,"class":6},"Organon and Co","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","MK0954, losartan potassium \u002F Duration of Treatment - 12 weeks",[13],{"name":14,"affiliation":15,"role":16},"Medical Monitor","Merck Sharp & Dohme LLC","STUDY_DIRECTOR",{"type":18,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100091376","phase-3-an-open-label-study-to-assess-the-efficacy-safety-and-tolerability-of-cozaar-plus-losartan-potassium-50mghydrochlorothiazide-125mg-possibly-titrated-up-to-cozaar-plus-f-losartan-potassium-100mghydrochlorothiazide-25mg-in-patients-with-essential-hypertension-0954a-325-100091376",false,"NCT00449111","An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg\u002FHydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg\u002FHydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)","An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg\u002FHydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg\u002FHydrochlorothiazide 25mg) in Patients With Essential Hypertension","Inclusion Criteria:\n\n* Patient treated with valsartan 80mg or irbesartan 150mg or vandesartan 8mg for at least 4 weeks prior to visit 1\n* Patient with systolic blood pressure between 140 to 159 mmhg and diastolic pressure between 90 to 99mmhg taken at visit 1\n\nExclusion Criteria:\n\n* History of angina pectoris that has not been stabilized in the past 6 weeks\n* History of clinically significant abnormal lab results or diseases\n* Myocardial infarction within the past 6 months\n* Stroke in the past 6 months","ALL","18 Years",{"count":29,"type":30},11,"ACTUAL","INTERVENTIONAL",[33],"PHASE3","Evaluate blood pressure after 6 weeks of treatment with COZAAR plus.",[36],"Hypertension","TERMINATED","2024-08-13",{"date":40,"type":30},"2024-08-15",{"date":42,"type":30},"2006-03-13",{"date":44,"type":30},"2006-09-30",{"name":5,"class":6}]